Tenaya Therapeutics, Inc. (TNYA) Key Statistics & Financial Ratios

Tenaya Therapeutics, Inc. (TNYA) — Price $0.66 HealthcareBiotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Tenaya Therapeutics, Inc. (TNYA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...

Stock Data

Price$0.66
Market Cap$143M
Enterprise Value$68.6M
Beta3.00
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-1.25
Price / Book2.07
P/S107.29
EV/EBITDA-0.71
EV/Sales51.37
EV/FCF-0.95
P/FCF-1.99
Earnings Yield-72.06%
FCF Yield-50.33%
Dividend Yield0.00%

Profitability

Gross Margin263.67%
EBIT Margin-7723.97%
EBITDA Margin-7188.09%
Operating Margin-7929.89%
Net Margin-7723.97%
Return on Equity-108.05%
Return on Assets-110.24%
Return on Invested Capital-136.78%
Return on Capital Employed-142.06%

Financial Health

Current Ratio4.52
Quick Ratio4.52
Cash Ratio4.11
Debt / Equity0.06
Debt / Assets4.22%
Net Debt / EBITDA0.77
Interest Coverage0.00
Piotroski F-Score3
Altman Z-Score-4.36

Per-Share Data

Revenue per share0.01
Book Value per share0.32
Cash per share0.36
FCF per share-0.33
Tangible Book Value per share0.32
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy6
Hold0
Sell0
Strong Sell0
Total analysts6
Avg rating (1-5)1.00

Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT

Explore sector: Healthcare · Biotechnology

More sections of TNYA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks